Reliability of measurements obtained with the Timed "Up & Go" Test in people with Parkinson disease
Reliability of measurements obtained with the Timed "Up & Go" Test in people with Parkinson disease
复制标题
DOI：
10.1093/ptj/81.2.810
复制
发表时间：
2001-02-01
期刊：
影响因子：
3.2
通讯作者：
Iansek, R
中科院分区：
文献类型：
--
作者：
Morris, S;Morris, ME;Iansek, R
背景和目的。定时“起身和行走”测试（TUC）用于测量患者执行包括行走和转身的连续运动任务的能力。本研究探讨了TUG评分在检测特发性帕金森病（PD）受试者活动性变化方面的重测信度、评分者间信度和敏感性。科目将12名PD患者的表现与12名年龄匹配的无PD对照受试者的表现进行比较。方法. PD受试者在停用左旋多巴12小时后（药物周期的“关闭“阶段）完成5项TUG试验，以及在给予左旋多巴1小时后（药物周期的“开启”阶段）完成另外5项试验。在两次治疗中均采用改良的韦伯斯特量表进行评分。对照受试者还进行了5次TUG试验。所有试验均由2名经验丰富的评分员进行录像和计时。随后，由3名经验丰富的临床医生和3名经验不足的临床医生对录像带进行评分。结果对于患有PD的受试者，会话内表现高度一致，“关闭“阶段的相关性（r）范围为0.80至0.98，“开启”阶段的相关性（r）范围为0.73至0.99。5项试验中比较受试者的表现也高度一致（r = .90-.97）。比较显示两组TUG试验1和2之间存在差异。删除试验1（实践试验）的数据进一步增强了重测信度。尽管评定者的经验水平不同，但他们的TUG评分非常一致（组内相关系数[3，1] = 0.87 - 0.99）。平均TUG评分在左旋多巴周期的“开”和“关“阶段之间以及在“开”阶段期间患有PD的受试者和对照受试者之间是不同的。结论和讨论。TUG测量的重测可靠性和评分者间可靠性很高，并且测量结果反映了根据左旋多巴使用的性能变化。TUG还可用于检测PD患者和无PD的老年人之间的表现差异。
Background and Purpose. The Timed "Up & Go" Test (TUC) is used to measure the ability of patients to perform sequential locomotor tasks that incorporate walking and turning. This study investigated the retest reliability, interrater reliability, and sensitivity of TUG scores in detecting changes in mobility in subjects with idiopathic Parkinson disease (PD). Subjects. The performance of 12 people with PD was compared with that of 12 age-matched comparison subjects without PD. Methods. The subjects with PD completed 5 trials of the TUG after withdrawal of levodopa for 12 hours ("off " phase of the medication cycle) as well as an additional 5 trials 1 hour after levodopa was administered ("on" phase of the medication cycle). They were scored on the Modified Webster Scale at both sessions. The comparison subjects also performed 5 TUG trials. All trials were videotaped and timed by 2 experienced raters. The videotape was later rated by 3 experienced clinicians and 3 inexperienced clinicians. Results. For the subjects with PD, within-session performance was highly consistent, with correlations (r) ranging from .80 to .98 for the "off " phase and from .73 to .99 for the "on" phase. The performance of the comparison subjects across the 5 trials was also highly consistent (r = .90-.97). Comparisons showed differences between trials 1 and 2 on the TUG for both groups. Removal of data for trial 1 (the practice trial) further enhanced retest reliability. There was close agreement in TUG scores among raters despite different levels of experience (intraclass correlation coefficient [3,1] = .87-.99). Mean TUG scores were different between the "on" and "off " phases of the levodopa cycle and between subjects with PD and comparison subjects during the "on" phase. Conclusion and Discussion. Retest reliability and interrater reliability of the TUG measurements were high, and the measurements reflected changes in performance according to levodopa use. The TUG can also be used to detect differences in performance between people with PD and elderly people without PD.